Last updated: February 19, 2026
This analysis details key considerations for obtaining and enforcing biopharmaceutical patents in Argentina, focusing on patentability requirements, enforcement challenges, and the strategic scope of claims. Argentina's patent law, Law No. 24,481, as amended by Law No. 25,916, and its implementing regulations, govern these aspects. The National Institute of Industrial Property (INPI) is the primary body responsible for examining patent applications.
What are the core patentability requirements for biopharmaceutical inventions in Argentina?
Argentine patent law requires inventions to be new, involve an inventive step, and have industrial applicability to be patentable. For biopharmaceuticals, these requirements translate into specific evidentiary and conceptual hurdles.
Novelty
An invention is considered novel if it has not been disclosed to the public anywhere in the world prior to the filing date of the patent application. This includes disclosure through publications, public use, sale, or any other means.
- Prior Art Search: A thorough prior art search is critical to establish novelty. This search must encompass Argentine and international patent databases, scientific literature, and any other publicly accessible information.
- Disclosure: Any disclosure of the invention by the inventor or their privy before the filing date can destroy novelty. This includes presentations at conferences, publications, or even discussions with third parties without adequate confidentiality agreements.
- Unity of Invention: Applications must relate to a single invention or a group of inventions linked by a "general inventive concept." This is particularly relevant for complex biopharmaceutical applications involving multiple compounds, formulations, or methods.
Inventive Step
An invention involves an inventive step if, considering the state of the art at the filing date, it is not obvious to a person skilled in the art. This is often the most challenging requirement for biopharmaceutical patents.
- Obviousness Assessment: Argentine patent examiners assess obviousness based on whether a skilled person, with ordinary knowledge and skill in the relevant technical field (e.g., molecular biology, pharmacology), would have arrived at the claimed invention without inventive effort, given the prior art.
- Unexpected Technical Effects: Demonstrating unexpected technical effects is crucial. This involves showing that the claimed biopharmaceutical produces a result that is superior to, or different from, what would have been predicted based on the prior art. Examples include:
- Significantly improved efficacy compared to existing treatments.
- Reduced side effects.
- A novel mechanism of action.
- Enhanced pharmacokinetic properties.
- Secondary Considerations: While not explicitly codified as separate considerations, evidence of commercial success, long-felt but unsolved needs, and failure of others can indirectly support the presence of an inventive step by indicating that the invention was not readily achievable.
- Enablement: The patent application must describe the invention in a manner that enables a person skilled in the art to carry it out. For biopharmaceuticals, this includes providing sufficient details on:
- The composition of matter (e.g., sequence of proteins, DNA constructs).
- Methods of production.
- Methods of use (e.g., dosage regimens, patient populations).
- Diagnostic methods if claimed.
Industrial Applicability
The invention must be capable of being made or used in any kind of industry, including agriculture. For biopharmaceuticals, this typically means the compound, formulation, or method can be produced and utilized in a practical, commercial sense.
- Commercial Viability: The claimed invention must have a practical use. A novel compound with no identifiable therapeutic or diagnostic application would likely fail this requirement.
- Reproducibility: The processes described for producing the biopharmaceutical must be reproducible.
Specific Exclusions and Limitations
Law No. 24,481 explicitly excludes certain subject matter from patentability. Article 4 outlines these exclusions, which are important for biopharmaceutical innovation:
- Methods of treatment, diagnostic, and surgical: Claims directed to methods of treatment of the human or animal body, diagnostic methods, and surgical methods are generally not patentable in Argentina. However, this exclusion does not extend to products, substances, or compositions used in these methods, such as novel drug compounds or formulations.
- Example: A patent claim for "A method of treating cancer comprising administering compound X" would be rejected.
- Example: A patent claim for "Compound X for use in treating cancer" or "A pharmaceutical composition comprising compound X and a pharmaceutically acceptable carrier" would likely be patentable if novelty, inventive step, and industrial applicability are met.
- Discoveries, scientific theories, and mathematical methods: Pure discoveries of naturally occurring substances without demonstrating their practical utility are not patentable. However, isolated and purified biological materials, such as specific DNA sequences or proteins with a defined function and utility, can be patentable if they meet the general patentability criteria.
- Living beings and essential biological processes: Law No. 24,481 (as amended) excludes "living beings as they exist in nature" and "essential biological processes for the reproduction of living beings." This exclusion requires careful interpretation regarding genetically modified organisms and their derived products. The patentability of gene sequences, recombinant proteins, and modified microorganisms depends heavily on whether they are considered "living beings as they exist in nature" or whether they represent a novel and inventive technical application of biological material. The patentability of isolated DNA sequences encoding human proteins, for instance, has been a subject of significant debate globally. In Argentina, patenting of such sequences is permissible if they are isolated from their natural environment and have a specific industrial application.
How are biopharmaceutical patents enforced in Argentina?
Enforcement of biopharmaceutical patents in Argentina involves civil litigation, typically through infringement lawsuits filed in federal courts.
Standing and Infringement
- Patent Holder's Rights: The patent holder has the exclusive right to prevent third parties from manufacturing, using, offering for sale, selling, or importing the patented invention without their authorization.
- Types of Infringement:
- Direct Infringement: Occurs when a third party directly makes, uses, sells, or imports the patented product or uses the patented process.
- Indirect Infringement: While not explicitly defined as a separate category in the same way as in some other jurisdictions, liability can arise for inducing or contributing to infringement. This is assessed under general principles of civil liability.
- Burden of Proof: The patent holder typically bears the burden of proving infringement. This often requires expert testimony and sophisticated technical analysis to demonstrate that the allegedly infringing product or process falls within the scope of the patent claims.
- Bolar Exemption: Argentina does not have a broad Bolar exemption similar to that in the U.S. or EU, which allows for activities related to regulatory approval of generic drugs before patent expiry. This means that activities undertaken by generic manufacturers in preparation for market entry can potentially constitute infringement if they involve the patented invention without authorization. However, this area is subject to evolving interpretations and potential legislative adjustments.
Preliminary Injunctions and Interim Measures
- Availability: Patent holders can seek preliminary injunctions to prevent irreparable harm while litigation is ongoing. This typically requires demonstrating:
- A likelihood of success on the merits of the infringement claim.
- Irreparable harm that cannot be adequately compensated by monetary damages.
- That the balance of hardships favors granting the injunction.
- Bond Requirement: Courts may require the patent holder to post a bond to cover potential damages to the defendant if the injunction is later found to have been wrongly granted.
- Evidence Required: Strong evidence of patent validity and infringement is needed to secure such measures. This often involves expert reports and clear demonstrations of the infringing activity.
Damages and Remedies
- Actual Damages: Courts can award damages to compensate the patent holder for the financial losses suffered due to infringement. This is typically calculated based on lost profits, reasonable royalties, or price erosion.
- Reasonable Royalty: If actual lost profits cannot be proven, a reasonable royalty rate is determined based on what a willing licensee would have paid a willing licensor for the patent rights.
- Enhanced Damages: In cases of willful or egregious infringement, courts may award enhanced damages, although this is less common than in some other jurisdictions.
- Permanent Injunctions: Upon finding infringement, courts can issue permanent injunctions prohibiting the infringer from continuing their activities.
Patent Term Extension
Argentina does not provide for patent term extensions to compensate for regulatory review delays, unlike in the U.S. or Europe. The patent term is strictly 20 years from the filing date.
What is the strategic scope of claims for biopharmaceutical patents in Argentina?
Crafting robust and enforceable claims is paramount for biopharmaceutical patent protection in Argentina. The scope of claims will determine the breadth of protection afforded to the invention and its susceptibility to challenge.
Claim Types and Drafting Strategies
- Composition of Matter Claims: These are generally the strongest claims as they provide broad protection against any unauthorized manufacture, use, or sale of the patented compound or formulation, regardless of the method of production or use.
- Example: "A pharmaceutical composition comprising compound [X] and a pharmaceutically acceptable carrier."
- Example: "A protein characterized by the amino acid sequence [SEQ ID NO: 1]."
- Method of Use Claims: These claims protect specific therapeutic, diagnostic, or industrial applications of a known or novel compound. As noted, direct method of treatment claims are unpatentable, but "use claims" are permissible.
- Example: "Compound [X] for use in treating inflammatory diseases."
- Example: "A diagnostic kit comprising antibodies that bind to biomarker [Y]."
- Process Claims: These protect the methods of manufacturing or producing the biopharmaceutical. While potentially narrower than composition of matter claims, they can be valuable if the patented process is novel and difficult to circumvent.
- Example: "A method for producing recombinant protein [Z] comprising the steps of..."
- Formulation Claims: These claims protect specific combinations of active ingredients with excipients, or specific delivery systems. They can be important for patenting improved formulations of known active compounds.
- Example: "A sustained-release pharmaceutical formulation comprising compound [X] encapsulated in biodegradable polymer [P]."
- Biomarker and Diagnostic Claims: Claims related to novel biomarkers and diagnostic methods can be complex. Patentability often hinges on demonstrating that the biomarker itself is novel and has a clear, industrially applicable utility beyond its mere existence. Diagnostic kits can also be patentable.
Claim Interpretation and Breadth
- Literal Interpretation: Argentine courts, like many others, interpret claims based on their plain meaning.
- Doctrine of Equivalents: While not as extensively developed or applied as in U.S. patent law, the doctrine of equivalents can be invoked to capture infringements that are not literally within the claim scope but perform substantially the same function in substantially the same way to achieve substantially the same result. However, its application in Argentina is more restrained and relies on broader principles of unfair competition and civil liability.
- Sufficiency of Disclosure: The scope of claims must be supported by the patent specification. Broad claims require detailed disclosure and enablement. Overly broad claims that are not adequately supported by the description can be invalidated during examination or litigation.
- Prior Art Limitations: The scope of claims is limited by the prior art. Claims cannot cover subject matter that was already known or obvious. Examiners and courts will consider the prior art when assessing infringement and validity.
Strategies for Broad Protection
- Generic Claims: Drafting claims broadly enough to cover foreseeable variations and modifications of the core invention is essential. This includes:
- Markush claims: For chemical entities, allowing for a generic representation of a class of compounds with variable substituents.
- Functional language: Describing the invention based on its function or properties, rather than solely its structure.
- Dependent Claims: Using dependent claims to further define and narrow the scope of independent claims provides fallback positions if broader claims are challenged.
- Multiple Claim Types: Filing applications with a diverse set of claims (composition, use, process, formulation) maximizes protection and provides multiple avenues for enforcement.
- Patent Families: Utilizing patent families to file applications in Argentina and other key jurisdictions ensures coordinated protection and leverages international prior art.
Navigating Exclusions and Specific Regulations
- Methods of Treatment: Careful drafting is required to avoid claiming methods of treatment directly. Focusing on "compound for use in treating..." or the therapeutic composition itself is key.
- Biological Material: The patentability of isolated genes, proteins, or modified organisms depends on demonstrating a clear industrial application and that they are not merely "living beings as they exist in nature." In vitro diagnostics, recombinant proteins, and isolated DNA sequences with a defined function are generally patentable.
Key Takeaways
Argentine patent law requires novelty, inventive step, and industrial applicability for biopharmaceutical patents. Methods of treatment are excluded, necessitating claims directed to compositions or their uses. Enforcement relies on civil litigation, with preliminary injunctions available. Claim scope is determined by literal interpretation and, to a lesser extent, the doctrine of equivalents, with breadth influenced by disclosure sufficiency and prior art. Strategic claim drafting, including composition of matter claims and robust use claims, is critical for effective protection.
FAQs
-
Are methods of treating cancer patentable in Argentina?
No, direct methods of treating the human or animal body are not patentable in Argentina. However, the pharmaceutical composition comprising a compound for treating cancer, or the compound itself for use in treating cancer, may be patentable if it meets the criteria for novelty, inventive step, and industrial applicability.
-
What is the typical patent term for biopharmaceutical inventions in Argentina?
The standard patent term in Argentina is 20 years from the filing date of the patent application. There are no provisions for patent term extension to compensate for regulatory review delays.
-
Can a patent be obtained for a naturally occurring protein isolated from its natural source?
Yes, a naturally occurring protein that has been isolated from its natural source and for which a specific industrial application is demonstrated can be patentable, provided it meets the requirements of novelty, inventive step, and industrial applicability. The mere discovery of a naturally occurring substance without a demonstrable practical utility is not patentable.
-
Does Argentina have a Bolar exemption for generic drug development?
Argentina does not have a broad Bolar exemption analogous to those found in the U.S. or European Union that specifically permits activities related to regulatory approval of generic drugs prior to patent expiry. Activities by generic manufacturers involving a patented invention could potentially constitute infringement.
-
How is infringement of a biopharmaceutical patent typically proven in Argentina?
Proof of infringement generally involves demonstrating that the allegedly infringing product or process falls within the scope of the patent claims. This often requires expert testimony and detailed technical analysis to compare the claimed invention with the alleged infringing subject matter. The patent holder bears the burden of proof.
Citations
[1] Law No. 24,481 on Inventions and Utility Models. (1995). Boletín Oficial de la República Argentina.
[2] Law No. 25,916 amending Law No. 24,481. (2004). Boletín Oficial de la República Argentina.
[3] National Institute of Industrial Property (INPI). (n.d.). Patent Examination Guidelines. (Specific guideline documents may vary; reference to INPI's operational procedures is implied).
